Anticorps Polyclonal de lapin anti-SPINT1/HAI-1

SPINT1/HAI-1 Polyclonal Antibody for WB, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

N° de cat : 27593-1-AP

Synonymes

HAI 1, HAI-1, SPINT1, HAI, HAI1

---

Galerie de données de validation

• 

  WB analysis of human placenta using 27593-1-AP

  human placenta tissue were subjected to SDS PAGE followed by western blot with 27593-1-AP (HAI-1 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of MCF-7 using 27593-1-AP

  MCF-7 cells were subjected to SDS PAGE followed by western blot with 27593-1-AP (HAI-1 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human lung cancer using 27593-1-AP

  Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 27593-1-AP (HAI-1 antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human lung cancer using 27593-1-AP

  Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 27593-1-AP (HAI-1 antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human brown disease using 27593-1-AP

  Immunohistochemical analysis of paraffin-embedded human brown disease slide using 27593-1-AP (HAI-1 antibody) at dilution of 1:800 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Applications testées

• Résultats positifs en WB: tissu placentaire humain, cellules MCF-7
• Résultats positifs en IHC: tissu de cancer du poumon humain, human brown disease; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:4000
• Immunohistochimie (IHC): IHC : 1:20-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

27593-1-AP cible SPINT1/HAI-1 dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: SPINT1/HAI-1 Protéine recombinante Ag26733
• Nom complet: serine peptidase inhibitor, Kunitz type 1
• Masse moléculaire calculée: 58 kDa
• Poids moléculaire observé: 58 kDa
• Numéro d’acquisition GenBank: BC004140
• Symbole du gène: HAI-1
• Identification du gène (NCBI): 6692
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is also named as SPINT1 and Kunitz-type protease inhibitor 1. HAI-1 is critical to control matriptase proteolytic activity (PMID: 25310042). HAI-1 inhibits matriptase activity through forming complex with activated matriptase (PMID: 30370662). matriptase, HAI‐1 also binds to and inhibits a variety of serine proteases including of hepsin, plasmin, prostasin, TMPRSS13 and HAT. HAI-1 as a cell-autonomous tumor suppressor that negatively regulates the HGF pathway (PMID: 25925948). HAI-1 is inhibitor of HGFAC (PMID: 9045658). HAI-1 inhibits serine protease activity of ST14/matriptase in vitro (PMID: 28710277). HAI-1 inhibits serine protease activity of TMPRSS13, via the BPTI/Kunitz inhibitor 1 domain (PMID: 20977675). HAI-1 expression is reduced in many cancer types, which is implicated in the progression of cancer and is associated with a worse prognosis in cancer patients (PMID: 30370662).

{{ptg:RelatedPrimaryAntibodies}}